<DOC>
	<DOC>NCT00527917</DOC>
	<brief_summary>This is a pilot clinical investigation. Patients who meet the eligibility criteria and provide signed informed consent will be randomized to receive either an active product (Uracyst®) or placebo intravesically via a bladder catheter weekly for 6 weeks, followed by 6 weeks of follow-up period.</brief_summary>
	<brief_title>A Pilot Clinical Investigation of the Efficacy and Safety of Uracyst® Versus Placebo in Patients With Interstitial Cystitis/Painful Bladder Syndrome.</brief_title>
	<detailed_description />
	<mesh_term>Cystitis</mesh_term>
	<mesh_term>Cystitis, Interstitial</mesh_term>
	<criteria>Are female of male patient 18 years or older Have been previously diagnosed with IC/PBS. Are willing to provide informed consent Available for the duration of the study including treatment and followup (12 weeks) Pregnant or lactating female. Are currently or have previously received investigational drugs within thirty (30) days of screening. Previous therapy for IC/PBS Have any medical condition/disease that could interfere with patient compliance or interfere with interpretation of the study results. Are unable or unwilling to comply with protocol requirements Are unable to read, understand, and provide written informed consent.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2009</verification_date>
	<keyword>IC/PBS</keyword>
	<keyword>Interstitial Cystitis/Painful Bladder Syndrome</keyword>
</DOC>